Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2024-12-26 00:00:00 ET · period of report 2024-12-23 · accession 0001140361-24-050461 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-12-26 | 2024-12-23+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | S - Sale+OE | $12.01 | -886.2K | 18.84M | -4% | -$10.64M |
| DM | 2024-12-26 | 2024-12-23+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $3.85 | +886.2K | 19.02M | +5% | +$3.41M |
| DM | 2024-12-26 | 2024-12-23+ | ROIV | Sukhatme Mayukh | Pres, CIO, Dir | M - OptEx | $0.00 | -886.2K | 16.10M | -5% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2024-12-24 | S | D | 185,946 | $12.00 | 18,836,547 | D | — | — | (F1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 2 | Common | Common Shares | 2024-12-26 | M | A | 689,495 | $3.85 | 19,526,042 | D | — | — | |
| 3 | Common | Common Shares | 2024-12-26 | S | D | 689,495 | $12.01 | 18,836,547 | D | — | — | (F1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 4 | Common | Common Shares | 2024-12-23 | S | D | 10,796 | $12.00 | 18,836,547 | D | — | — | (F1) The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 5 | Common | Common Shares | 2024-12-23 | M | A | 10,796 | $3.85 | 18,847,343 | D | — | — | |
| 6 | Common | Common Shares | 2024-12-24 | M | A | 185,946 | $3.85 | 19,022,493 | D | — | — | |
| 7 | Derivative | Stock Option (Right to Buy) | 2024-12-26 | M | D | 689,495 | $0.00 | 15,224,363 | D | $3.85 · — to 2032-04-19 | 689,495 Common Stock | (F2) Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |
| 8 | Derivative | Stock Option (Right to Buy) | 2024-12-24 | M | D | 185,946 | $0.00 | 15,913,858 | D | $3.85 · — to 2032-04-19 | 185,946 Common Stock | (F2) Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |
| 9 | Derivative | Stock Option (Right to Buy) | 2024-12-23 | M | D | 10,796 | $0.00 | 16,099,804 | D | $3.85 · — to 2032-04-19 | 10,796 Common Stock | (F2) Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |